Yuvraj_pawp, Author at Pharma Advancement

ICSE China 2016, hosted by UBM EMEA and China Chamber of Commerce of Medicines & Health Products Importers & Exporters...

How pharma can stay competitive in the digital world

by Yuvraj_pawp

1st February 2016

As drugmakers seek new ways to incorporate digital technology into the way they do business, questions persist about whether the...

Nutrition and health bars expand market share by tying into wellness, athleticism

by Yuvraj_pawp

18th January 2016

Nutrition and health bars are stealing market share from the category leading snack and cereal bars in part because they...

Merck’s BRIDION® (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery

by Yuvraj_pawp

22nd December 2015

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug...

Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir

by Yuvraj_pawp

22nd December 2015

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for...

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

by Yuvraj_pawp

22nd December 2015

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration...

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

by Yuvraj_pawp

22nd December 2015

KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress...

CABBVIE ANNOUNCES NEW ENGLAND JOURNAL OF MEDICINE ONLINE PUBLICATION OF VENETOCLAX PHASE 1 DATA IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

by Yuvraj_pawp

21st December 2015

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the online publication of new data in the New England Journal...

IBRUTINIB (IMBRUVICA®) COMBINATION DATA SHOW PROMISE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

by Yuvraj_pawp

21st December 2015

AbbVie , a global biopharmaceutical company, announced preliminary data from the ongoing Phase 1/2b PCYC-1119 trial suggesting that the combination of...

IMBRUVICA® (IBRUTINIB) PHASE 3 RAY DATA SHOW SIGNIFICANT REDUCTIONS IN DISEASE PROGRESSION VERSUS TEMSIROLIMUS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS

by Yuvraj_pawp

21st December 2015

- IMBRUVICA ASSOCIATED WITH SIGNIFICANT IMPROVEMENTS IN KEY ENDPOINTS INCLUDING REDUCTION OF THE RISK OF DISEASE PROGRESSION OR DEATH VERSUS...

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

Robots and AI in Drug Discovery Are Transforming Medicine

Stringent Policy around COVID Vaccines Laid by FDA

Pharmaceutical Chemicals Market Booms with Rising API Demand

Next in Pharma 2025: Innovations Shaping the Future

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

AI Revolutionizing Drug Discovery and Clinical Development

China’s Super Me-Too Drug Development: A New Pharma Frontier

Asia Pacific Omics-Based Clinical Trials Market Growth

Yuvraj_pawp

ICSE China 2016 – A gala event for pharma CRO & CMO industry

How pharma can stay competitive in the digital world

Nutrition and health bars expand market share by tying into wellness, athleticism

Merck’s BRIDION® (sugammadex) Receives FDA Approval for the Reversal of Neuromuscular Blockade Induced by Rocuronium and Vecuronium in Adults Undergoing Surgery

Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir

FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma

Merck’s KEYTRUDA® (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1

CABBVIE ANNOUNCES NEW ENGLAND JOURNAL OF MEDICINE ONLINE PUBLICATION OF VENETOCLAX PHASE 1 DATA IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

IBRUTINIB (IMBRUVICA®) COMBINATION DATA SHOW PROMISE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

IMBRUVICA® (IBRUTINIB) PHASE 3 RAY DATA SHOW SIGNIFICANT REDUCTIONS IN DISEASE PROGRESSION VERSUS TEMSIROLIMUS IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS

Qucik Links

About Us

Subscribe Us

System

Resources

Retrieve your password